
U.S. equities traded in the green at noon on Friday as investors returned to the markets following the Christmas holiday on Thursday, with markets poised to end the week on a winning note.
The Santa Claus rally began on Wednesday on a positive note, with the S&P 500 notching a new all-time high.
The SPDR S&P 500 ETF (SPY), which mirrors the S&P 500 index, was up 0.08% at the time of writing, while the Invesco QQQ Trust (QQQ), which mirrors the Nasdaq 100 index, gained 0.16%. The SPDR Dow Jones Industrial Average ETF Trust (DIA), which tracks the Dow Jones Industrial Average, rose 0.01%.
Nvidia Corp. (NVDA)
Nvidia’s shares were up nearly 2% in Friday’s midday trade after the company entered into a non-exclusive licensing agreement with Groq for its inference technology, with the deal value pegged at $20 billion.
NVDA stock is up 10% over the past five trading sessions.
Sidus Space Inc. (SIDU)
Sidus Space shares continued to gain on Friday, up more than 22% in the midday session after the company was awarded a contract earlier this week under the Missile Defense Agency’s Scalable Homeland Innovative Enterprise Layered Defense (SHIELD) program.
SIDU stock is up 237% over the past five trading sessions.
Coupang Inc. (CPNG)
Coupang shares gained over 9% in Friday’s midday trade after the company said that all the leaked customer information in a recent data breach had been deleted by the suspect, according to a Reuters report. Coupang stated that the suspect was a former employee.
CPNG stock is up 10% over the past five trading sessions.
Vanda Pharmaceuticals Inc. (VNDA)
Vanda Pharmaceuticals shares gained nearly 8% in Friday’s pre-market trade before paring some of the gains to hover 3% higher, ahead of a pending U.S. Food and Drug Administration (FDA) decision on its motion-sickness prevention drug, Tradipitant.
VNDA stock is up 7% over the past five trading sessions.
ImmuCell Corp. (ICCC)
ImmuCell shares were up nearly 10% in Friday’s midday trade after the company announced a 50% expansion of its First Defense field sales force and plans to scale up manufacturing of the drug. The company also said it is pausing its Re-Tain treatment for cows after receiving an “Incomplete Letter” from the FDA.
ICCC stock is up 2% over the past five trading sessions.
For updates and corrections, email newsroom[at]stocktwits[dot]com.<
Stay updated with all the latest Business NewsShare Market NewsIPOsGold PriceDA Hike8th Pay CommissionAsianet News Official App